key: cord-0811462-g0lwmd50
authors: Al-Otaibi, Mohamad; Iftikhar, Omer; Brailovsky, Yevgeniy; Rali, Parth; Islam, Sabrina; Narewski, Erin; Choi, Eric; Cohen, Gary; Bashir, Riyaz; Lakhter, Vladimir
title: Catheter-Directed Thrombolysis of Iliocaval Thrombosis in Patients with COVID-19
date: 2020-08-25
journal: JACC Case Rep
DOI: 10.1016/j.jaccas.2020.07.057
sha: 4895f3191963b82d393bc24e8b564c1c20b5b830
doc_id: 811462
cord_uid: g0lwmd50

Abstract We present the characteristics and outcomes of the first two cases of catheter-directed thrombolysis performed in patients presenting with COVID-19 related iliocaval thrombosis

Deep vein thrombosis (DVT), a common disorder affecting approximately 600,000

patients each year in the United States (1), is frequently complicated by a debilitating postthrombotic syndrome (2) . SARS-CoV-2 virus is associated with a hypercoagulable state and a 16 to 27% incidence of DVT and pulmonary embolism (3, 4) . As of June 1 st 2020, the US Centers for Disease Control and Prevention had reported over 1.8 million cases of COVID-19 in the United States, over 75% of them are <65 years of age (5) , and a high proportion presenting with, or destined to develop thrombosis of large veins, including iliocaval thrombosis. In these patients, anticoagulation alone is often insufficient and, in absence of COVID-19, they would be considered candidates for catheter-directed thrombolysis (CDT) to alleviate symptoms and improve quality of life (6) .

Current guidelines recommend treatment of proximal DVT in hospitalized COVID-19 patients with Low molecular weight heparin (LMWH), they however did not address the use of advanced therapies like CDT (7) . Our cases illustrate the potential role of CDT in selected low bleeding risk young patients. To the best of our knowledge, CDT of symptomatic iliocaval thrombosis in COVID-19 patients has not been reported, which is likely because of the potential risks of bleeding complications and viral transmission to the catheterization laboratory staff. We report 2 cases of COVID-19 patients presenting with severely symptomatic iliofemoral and inferior vena cava (IVC) thrombosis, successfully treated with CDT. occlusive thrombosis from the IVC filter, at the renal veins confluence, to the right FV (Fig 2A) .

There was also evidence of chronic DVT in the left lower extremity with atretic left common iliac vein (CIV) and EIV. The patient was anticoagulated using IV UFH at a rate of 2,100 units/hr for 72 h with serial therapeutic PTTs without any change in the swelling or pain. The risks and benefits of CDT including the conflict of interest associated with the use of Bashir Endovascular Catheter were explained to the patient after which a written consent was obtained.

After obtaining successful ultrasound-guided right popliteal venous access, venography revealed the presence of a thrombus extending from the IVC filter to the right popliteal vein ( Figure 2B ).

Manual thrombectomy was performed with an 8 F multipurpose guiding catheter. Using a BEC+40 catheter, CDT was performed by delivering a 6-mg pulse of rtPA via the infusion basket, which was sequentially expanded along the infra-renal IVC, right CIV, EIV, CFV and 

Venous thromboembolism: a public health concern

Relationship between deep venous thrombosis and the postthrombotic syndrome. Archives of internal medicine

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Incidence of venous thromboembolism in hospitalized patients with COVID-19

Endovascular thrombus removal for acute iliofemoral deep vein thrombosis: analysis from a stratified multicenter randomized trial

Scientific and Standardization Committee Communication: Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID 19

Catheter-directed thrombolysis in COVID-19 pneumonia with acute PE: Thinking beyond the guidelines

The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States